GSK Blasts Senate Report On Avandia Risks

Law360, New York (February 24, 2010, 4:13 PM EST) -- GlaxoSmithKline PLC fired back Wednesday at a U.S. Senate Finance Committee report that alleges the company has concealed data suggesting an increased risk of heart attack linked to its diabetes drug Avandia, calling the report inaccurate and incomplete.

In a statement issued along with a 30-page rebuttal of the report, GSK said it rejected any suggestion that it had hidden safety data about the drug and “respectfully disagrees with the committee’s decision to publish a staff report with errors of fact, omissions and inferences.”

Contrary to...
To view the full article, register now.